Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Current Valuation Ratios
| Humana Inc. | Abbott Laboratories | Elevance Health Inc. | Intuitive Surgical Inc. | Medtronic PLC | UnitedHealth Group Inc. | Health Care Equipment & Services | Health Care | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||
| Current share price (P) | $266.32 | ||||||||||
| No. shares of common stock outstanding | 120,411,343 | ||||||||||
| Growth rate (g) | 17.47% | ||||||||||
| Earnings per share (EPS) | $20.67 | ||||||||||
| Next year expected EPS | $24.28 | ||||||||||
| Operating profit per share | $33.33 | ||||||||||
| Sales per share | $874.54 | ||||||||||
| Book value per share (BVPS) | $135.05 | ||||||||||
| Valuation Ratios (Price Multiples) | |||||||||||
| Price to earnings (P/E) | 12.88 | 30.13 | 16.48 | 56.87 | 27.93 | 29.41 | 23.73 | 40.83 | |||
| Price to next year expected earnings | 10.97 | 27.94 | 14.74 | 49.86 | 27.56 | 26.20 | 21.35 | 36.44 | |||
| Price-earnings-growth (PEG) | 0.74 | 3.84 | 1.39 | 4.05 | 20.39 | 2.40 | 2.13 | 3.39 | |||
| Price to operating profit (P/OP) | 7.99 | 24.41 | 14.20 | 55.14 | 20.74 | 18.70 | 17.52 | 36.66 | |||
| Price to sales (P/S) | 0.30 | 4.43 | 0.47 | 16.14 | 3.69 | 0.80 | 1.53 | 4.69 | |||
| Price to book value (P/BV) | 1.97 | 3.77 | 2.13 | 9.11 | 2.71 | 3.77 | 4.07 | 7.92 | |||
Based on: 10-K (reporting date: 2023-12-31).
If the company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.
Otherwise, if the company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.
Historical Valuation Ratios (Summary)
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
An analysis of valuation multiples from 2019 through 2023 reveals a general trend of volatility across all metrics, with a notable contraction in valuation multiples occurring in the final year of the period.
- Price to Earnings (P/E) Ratio
- The P/E ratio experienced fluctuations, beginning at 18.10 in 2019 and decreasing to 14.48 in 2020. A recovery followed, with the ratio ascending to a peak of 22.52 in 2022 before retreating to 17.64 in 2023, returning to a level comparable to the 2019 baseline.
- Price to Operating Profit (P/OP) Ratio
- The P/OP ratio demonstrated significant variance, falling from 15.35 in 2019 to a low of 9.78 in 2020. This was followed by a sharp increase to 17.08 in 2021 and a relatively stable 16.63 in 2022, before declining substantially to 10.94 in 2023.
- Price to Sales (P/S) Ratio
- A period of relative stability was observed in the P/S ratio between 2019 and 2022, with values ranging between 0.64 and 0.76. However, a sharp contraction occurred in 2023, where the ratio dropped to 0.42, marking the lowest valuation relative to sales in the observed timeframe.
- Price to Book Value (P/BV) Ratio
- The P/BV ratio exhibited an inconsistent trend, declining from 4.07 in 2019 to 3.34 in 2021, before peaking at 4.13 in 2022. A significant decrease followed in 2023, with the ratio falling to 2.70, indicating a reduction in the market premium over the company's book value.
Collectively, the multiples indicate a peak in market valuation around 2022, followed by a comprehensive compression in 2023 across earnings, operating profit, sales, and book value metrics.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Price to Earnings (P/E)
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 120,653,315 | 124,974,862 | 126,633,599 | 128,861,929 | 132,106,497 | |
| Selected Financial Data (US$) | ||||||
| Net income attributable to Humana (in millions) | 2,489) | 2,806) | 2,933) | 3,367) | 2,707) | |
| Earnings per share (EPS)2 | 20.63 | 22.45 | 23.16 | 26.13 | 20.49 | |
| Share price1, 3 | 363.98 | 505.69 | 424.71 | 378.33 | 370.99 | |
| Valuation Ratio | ||||||
| P/E ratio4 | 17.64 | 22.52 | 18.34 | 14.48 | 18.10 | |
| Benchmarks | ||||||
| P/E Ratio, Competitors5 | ||||||
| Abbott Laboratories | 34.57 | 26.76 | 29.13 | — | — | |
| Elevance Health Inc. | 19.80 | 19.20 | 18.13 | — | — | |
| Intuitive Surgical Inc. | 74.11 | 64.99 | 59.94 | — | — | |
| Medtronic PLC | 30.94 | 23.38 | 46.56 | — | — | |
| UnitedHealth Group Inc. | 20.53 | 22.46 | 26.03 | — | — | |
| P/E Ratio, Sector | ||||||
| Health Care Equipment & Services | 25.86 | 24.26 | 28.98 | — | — | |
| P/E Ratio, Industry | ||||||
| Health Care | 30.62 | 21.22 | 21.55 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 Data adjusted for splits and stock dividends.
2 2023 Calculation
EPS = Net income attributable to Humana ÷ No. shares of common stock outstanding
= 2,489,000,000 ÷ 120,653,315 = 20.63
3 Closing price as at the filing date of Humana Inc. Annual Report.
4 2023 Calculation
P/E ratio = Share price ÷ EPS
= 363.98 ÷ 20.63 = 17.64
5 Click competitor name to see calculations.
The equity valuation between 2019 and 2023 is characterized by a period of price expansion and subsequent correction, while earnings per share remained relatively stable. The relationship between share price and earnings resulted in a fluctuating price-to-earnings (P/E) multiple that peaked in 2022 before returning to historical norms.
- Share Price Trajectory
- A steady increase in share price was observed from 2019 through 2022, with the value rising from 370.99 US$ to a peak of 505.69 US$. This growth trend reversed significantly in 2023, as the price declined to 363.98 US$, effectively erasing the gains made over the preceding four years.
- Earnings per Share (EPS) Trends
- Earnings per share reached a maximum of 26.13 US$ in 2020. Following this peak, a gradual downward trend was observed over the next three years, with EPS declining to 22.45 US$ in 2022 and finishing at 20.63 US$ in 2023. The 2023 earnings level represents a return to the baseline established in 2019.
- Price-to-Earnings (P/E) Ratio Interpretation
- The P/E ratio exhibited significant volatility. A contraction to 14.48 occurred in 2020, coinciding with the peak in EPS. Conversely, the ratio expanded to its highest point of 22.52 in 2022, driven by the peak share price despite falling earnings. By 2023, the P/E ratio corrected to 17.64, indicating a normalization of the valuation multiple in alignment with the reduction in share price and the stabilization of earnings.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Price to Operating Profit (P/OP)
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 120,653,315 | 124,974,862 | 126,633,599 | 128,861,929 | 132,106,497 | |
| Selected Financial Data (US$) | ||||||
| Income from operations (in millions) | 4,013) | 3,800) | 3,148) | 4,986) | 3,192) | |
| Operating profit per share2 | 33.26 | 30.41 | 24.86 | 38.69 | 24.16 | |
| Share price1, 3 | 363.98 | 505.69 | 424.71 | 378.33 | 370.99 | |
| Valuation Ratio | ||||||
| P/OP ratio4 | 10.94 | 16.63 | 17.08 | 9.78 | 15.35 | |
| Benchmarks | ||||||
| P/OP Ratio, Competitors5 | ||||||
| Abbott Laboratories | 30.54 | 22.18 | 24.45 | — | — | |
| Elevance Health Inc. | 15.57 | 15.05 | 15.70 | — | — | |
| Intuitive Surgical Inc. | 75.42 | 54.49 | 56.11 | — | — | |
| Medtronic PLC | 21.20 | 20.48 | 37.44 | — | — | |
| UnitedHealth Group Inc. | 14.20 | 15.89 | 18.77 | — | — | |
| P/OP Ratio, Sector | ||||||
| Health Care Equipment & Services | 19.09 | 18.47 | 22.66 | — | — | |
| P/OP Ratio, Industry | ||||||
| Health Care | 27.48 | 16.58 | 18.20 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 Data adjusted for splits and stock dividends.
2 2023 Calculation
Operating profit per share = Income from operations ÷ No. shares of common stock outstanding
= 4,013,000,000 ÷ 120,653,315 = 33.26
3 Closing price as at the filing date of Humana Inc. Annual Report.
4 2023 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 363.98 ÷ 33.26 = 10.94
5 Click competitor name to see calculations.
An analysis of the price-to-operating profit (P/OP) metrics from 2019 to 2023 reveals a period of significant volatility, where the relationship between market valuation and operational performance shifted inconsistently over the five-year horizon.
- Share Price Trajectory
- The share price experienced a sustained increase from 2019 through 2022, rising from 370.99 US$ to a peak of 505.69 US$. This growth trend reversed sharply in 2023, with the price declining to 363.98 US$, effectively erasing the gains made over the preceding four years and falling slightly below the 2019 baseline.
- Operating Profit per Share Performance
- Operating profit per share exhibited a non-linear trend. A substantial peak was observed in 2020 at 38.69 US$, followed by a sharp contraction to 24.86 US$ in 2021. From 2021 onward, a steady recovery trend is evident, with profits increasing to 30.41 US$ in 2022 and reaching 33.26 US$ by the end of 2023.
- P/OP Ratio Dynamics
- The P/OP ratio fluctuated significantly, reflecting the divergence between market sentiment and operating results. The ratio reached a five-year low of 9.78 in 2020, driven by the surge in operating profit. Conversely, the ratio peaked in 2021 at 17.08, as the share price continued to rise while operating profits declined. In 2023, the ratio compressed to 10.94; this compression was primarily driven by the significant decrease in share price, occurring despite the fact that operating profit per share had improved from the previous year.
Overall, the data indicates that the market valuation of the company was not consistently aligned with its operating profitability. The lowest valuation multiples occurred during periods of peak operational efficiency (2020) or significant price corrections (2023), while the highest multiples coincided with a period of declining operating profit (2021).
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Price to Sales (P/S)
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 120,653,315 | 124,974,862 | 126,633,599 | 128,861,929 | 132,106,497 | |
| Selected Financial Data (US$) | ||||||
| External revenues (in millions) | 105,305) | 92,488) | 82,877) | 76,001) | 64,387) | |
| Sales per share2 | 872.79 | 740.05 | 654.46 | 589.79 | 487.39 | |
| Share price1, 3 | 363.98 | 505.69 | 424.71 | 378.33 | 370.99 | |
| Valuation Ratio | ||||||
| P/S ratio4 | 0.42 | 0.68 | 0.65 | 0.64 | 0.76 | |
| Benchmarks | ||||||
| P/S Ratio, Competitors5 | ||||||
| Abbott Laboratories | 4.93 | 4.25 | 4.78 | — | — | |
| Elevance Health Inc. | 0.70 | 0.74 | 0.81 | — | — | |
| Intuitive Surgical Inc. | 18.71 | 13.81 | 17.89 | — | — | |
| Medtronic PLC | 3.72 | 3.72 | 5.57 | — | — | |
| UnitedHealth Group Inc. | 1.25 | 1.40 | 1.58 | — | — | |
| P/S Ratio, Sector | ||||||
| Health Care Equipment & Services | 1.66 | 1.71 | 2.07 | — | — | |
| P/S Ratio, Industry | ||||||
| Health Care | 3.52 | 3.11 | 3.28 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 Data adjusted for splits and stock dividends.
2 2023 Calculation
Sales per share = External revenues ÷ No. shares of common stock outstanding
= 105,305,000,000 ÷ 120,653,315 = 872.79
3 Closing price as at the filing date of Humana Inc. Annual Report.
4 2023 Calculation
P/S ratio = Share price ÷ Sales per share
= 363.98 ÷ 872.79 = 0.42
5 Click competitor name to see calculations.
An analysis of the valuation metrics from 2019 to 2023 reveals a divergence between the company's revenue growth and its market valuation. While sales per share grew consistently throughout the period, the price-to-sales (P/S) ratio experienced an overall decline, culminating in a significant contraction in 2023.
- Sales per Share Growth
- A consistent upward trend is observed in sales per share, which rose from 487.39 US$ in 2019 to 872.79 US$ in 2023. This represents uninterrupted annual growth in revenue generation on a per-share basis over the five-year span.
- Share Price Fluctuations
- The share price demonstrated an initial growth phase from 2019 to 2022, increasing from 370.99 US$ to a peak of 505.69 US$. However, this trend reversed sharply in 2023, with the price declining to 363.98 US$, falling below the 2019 baseline.
- Price-to-Sales (P/S) Ratio Analysis
- The P/S ratio remained below 1.0 for the entire duration of the analysis. After starting at 0.76 in 2019, the ratio stabilized between 0.64 and 0.68 from 2020 through 2022. A substantial decrease occurred in 2023, with the ratio dropping to 0.42. This suggests that despite the record-high sales per share in 2023, the market valuation relative to revenue reached its lowest point in the period analyzed.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Price to Book Value (P/BV)
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 120,653,315 | 124,974,862 | 126,633,599 | 128,861,929 | 132,106,497 | |
| Selected Financial Data (US$) | ||||||
| Stockholders’ equity (in millions) | 16,262) | 15,311) | 16,080) | 13,728) | 12,037) | |
| Book value per share (BVPS)2 | 134.78 | 122.51 | 126.98 | 106.53 | 91.12 | |
| Share price1, 3 | 363.98 | 505.69 | 424.71 | 378.33 | 370.99 | |
| Valuation Ratio | ||||||
| P/BV ratio4 | 2.70 | 4.13 | 3.34 | 3.55 | 4.07 | |
| Benchmarks | ||||||
| P/BV Ratio, Competitors5 | ||||||
| Abbott Laboratories | 5.12 | 5.06 | 5.75 | — | — | |
| Elevance Health Inc. | 3.02 | 3.19 | 3.07 | — | — | |
| Intuitive Surgical Inc. | 10.01 | 7.78 | 8.59 | — | — | |
| Medtronic PLC | 2.26 | 2.24 | 3.26 | — | — | |
| UnitedHealth Group Inc. | 5.18 | 5.81 | 6.27 | — | — | |
| P/BV Ratio, Sector | ||||||
| Health Care Equipment & Services | 4.43 | 4.46 | 5.01 | — | — | |
| P/BV Ratio, Industry | ||||||
| Health Care | 5.94 | 5.26 | 5.48 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 Data adjusted for splits and stock dividends.
2 2023 Calculation
BVPS = Stockholders’ equity ÷ No. shares of common stock outstanding
= 16,262,000,000 ÷ 120,653,315 = 134.78
3 Closing price as at the filing date of Humana Inc. Annual Report.
4 2023 Calculation
P/BV ratio = Share price ÷ BVPS
= 363.98 ÷ 134.78 = 2.70
5 Click competitor name to see calculations.
An analysis of the valuation metrics from 2019 through 2023 reveals a divergence between the growth of the underlying book value and the volatility of the market price. While the intrinsic equity value per share has trended upward over the five-year period, the market valuation multiple has experienced significant fluctuations, ending the period at its lowest point.
- Book Value per Share (BVPS)
- A general upward trajectory is observed in the book value per share, which increased from $91.12 in 2019 to $134.78 in 2023. Despite a slight contraction in 2022, where the value dipped to $122.51, the overall trend indicates a consistent expansion of the company's equity base over the analyzed timeframe.
- Share Price Performance
- The share price exhibited a period of growth between 2019 and 2022, ascending from $370.99 to a peak of $505.69. This growth trend reversed sharply in 2023, with the price declining to $363.98, effectively erasing the gains made over the preceding three years and returning to levels consistent with the 2019-2020 period.
- Price to Book Value (P/BV) Ratio
- The P/BV ratio demonstrates significant volatility, fluctuating from a high of 4.13 in 2022 to a low of 2.70 in 2023. Between 2019 and 2021, a gradual compression was noted as the ratio moved from 4.07 to 3.34. The spike in 2022 was driven primarily by the surge in share price, while the subsequent drop to 2.70 in 2023 reflects a simultaneous decrease in market price and an increase in book value, indicating a notable contraction in the premium the market is willing to pay over the company's accounting value.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?